Holotoxin activity of botulinum neurotoxin subtype A4 originating from a nontoxigenic Clostridium botulinum expression system

Applied and Environmental Microbiology

Volumn 80, Issue 23, 2014, Pages 7415-7422

  Bradshaw, Marite ^a   Tepp, William H ^a   Whitemarsh, Regina C M ^a   Pellett, Sabine ^a   Johnson, Eric A ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIA; ESCHERICHIA COLI; PURIFICATION; TOXIC MATERIALS;

AMINO ACID SUBSTITUTION; BOTULINUM NEUROTOXINS; CLOSTRIDIUM BOTULINUM; COMPARATIVE ANALYSIS; COMPLEX COMPONENTS; EXPRESSION SYSTEM; LIGHT CHAIN; NEURONAL CELL;

CLOSTRIDIUM;

BACTERIUM; GENE EXPRESSION; MUTATION; NEUROLOGY; PROTEIN; RECOMBINATION; RODENT; SOLUBILIZATION; TOXIN;

CLOSTRIDIUM BOTULINUM;

ANTITOXIN; BOTULINUM TOXIN A; GLYCOSIDE; RECOMBINANT PROTEIN; STICHOPOSIDE; TRITERPENE;

AMINO ACID SUBSTITUTION; ANIMAL; CELL CULTURE; CHEMISTRY; CLOSTRIDIUM BOTULINUM; DRUG EFFECTS; ESCHERICHIA COLI; GENE EXPRESSION; GENETICS; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MOUSE; NERVE CELL; PROTEIN STABILITY; SERODIAGNOSIS;

AMINO ACID SUBSTITUTION; ANIMALS; ANTITOXINS; BOTULINUM TOXINS, TYPE A; CELLS, CULTURED; CLOSTRIDIUM BOTULINUM; ESCHERICHIA COLI; GENE EXPRESSION; GLYCOSIDES; HUMANS; MICE; NEURONS; NEUTRALIZATION TESTS; PROTEIN STABILITY; RECOMBINANT PROTEINS; TRITERPENES;

EID: 84910107318     PISSN: 00992240     EISSN: 10985336     Source Type: Journal    
DOI: 10.1128/AEM.01795-14     Document Type: Article

References (49)

1. Schantz EJ, Johnson EA. 1992. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol. Rev. 56:80-99.
2. Rossetto O, Pirazzini M, Montecucco C. 2014. Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat. Rev. Microbiol. 12:535-549. http://dx.doi.org/10.1038/nrmicro3295.
3. Barash JR, Arnon SS. 2014. A novel strain of Clostridium botulinum that produces type B and typeHbotulinum toxins. J. Infect. Dis. 209:183-191. http://dx.doi.org/10.1093/infdis/jit449.
4. Dover N, Barash JR, Hill KK, Xie G, Arnon SS. 2014. Molecular characterization of a novel botulinum neurotoxin type H gene. J. Infect. Dis. 209:192-202. http://dx.doi.org/10.1093/infdis/jit450.
5. Hill KK, Smith TJ, Helma CH, Ticknor LO, Foley BT, Svensson RT, Brown JL, Johnson EA, Smith LA, Okinaka RT, Jackson PJ, Marks JD. 2007. Genetic diversity among botulinum neurotoxin-producing clostridial strains. J. Bacteriol. 189:818-832. http://dx.doi.org/10.1128/JB.01180-06.
6. Hill KK, Smith TJ. 2013. Genetic diversity within Clostridium botulinum serotypes, botulinum neurotoxin gene clusters and toxin subtypes. Curr. Top. Microbiol. Immunol. 364:1-20. http://dx.doi.org/10.1007/978-3-642-33570-9_1.
7. Smith TJ, Lou J, Geren IN, Forsyth CM, Tsai R, Laporte SL, Tepp WH, Bradshaw M, Johnson EA, Smith LA, Marks JD. 2005. Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect. Immun. 73:5450-5457. http://dx.doi.org/10.1128/IAI.73.9.5450-5457.2005.
8. Popoff MR, Bouvet P. 2013. Genetic characteristics of toxigenic clostridia and toxin gene evolution. Toxicon 75:63-89. http://dx.doi.org/10.1016/j.toxicon.2013.05.003.
9. US Government Printing Office. 18 March 2005. Electronic Code of Federal Regulations (e-CFR). Title 42: public health, part 73-select agents and toxins. http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&SID=8a4be60456973b 5ec6bef5dfeaffd49a&r=PART&n=42y1.0.1.6.61.
10. National Institutes of Health. 29 March 2012. United States Government policy for oversight of life sciences dual use research of concern. http://osp.od.nih.gov/office-biotechnology-activities/biosecurity/dual-use-research-concern.
11. Dressler D. 2012. Clinical applications of botulinum toxin. Curr. Opin. Microbiol. 15:325-336. http://dx.doi.org/10.1016/j.mib.2012.05.012.
12. Whitemarsh RC, Tepp WH, Bradshaw M, Lin G, Pier CL, Scherf JM, Johnson EA, Pellett S. 2013. Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro. Infect. Immun. 81:3894-3902. http://dx.doi.org/10.1128/IAI.00536-13.
13. Whitemarsh RC, Tepp WH, Johnson EA, Pellett S. 2014. Persistence of botulinum neurotoxin A subtypes 1-5 in primary rat spinal cord cells. PLoS One 9:e90252. http://dx.doi.org/10.1371/journal.pone.0090252.
14. Wang D, Krilich J, Pellett S, Baudys J, Tepp WH, Barr JR, Johnson EA, Kalb SR. 2013. Comparison of the catalytic properties of the botulinum neurotoxin subtypes A1 and A5. Biochim. Biophys. Acta 1834:2722-2728. http://dx.doi.org/10.1016/j.bbapap.2013.09.007.
15. Tepp WH, Lin G, Johnson EA. 2012. Purification and characterization of a novel subtype A3 botulinum neurotoxin. Appl. Environ. Microbiol. 78: 3108-3113. http://dx.doi.org/10.1128/AEM.07967-11.
16. Pier CL, Chen C, Tepp WH, Lin G, Janda KD, Barbieri JT, Pellett S, Johnson EA. 2011. Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1. FEBS Lett. 585:199-206. http://dx.doi.org/10.1016/j.febslet.2010.11.045.
17. Johnson EA, Bradshaw M. 2001. Clostridium botulinum and its neurotoxins: a metabolic and cellular perspective. Toxicon 39:1703-1722. http://dx.doi.org/10.1016/S0041-0101(01)00157-X.
18. Bonventre PF, Kempe LL. 1960. Physiology of toxin production by Clostridium botulinum types A and B. I. Growth, autolysis, and toxin production. J. Bacteriol. 79:18-23.
19. Bonventre PF, Kempe LL. 1960. Physiology of toxin production by Clostridium botulinum types A and B. IV. Activation of the toxin. J. Bacteriol. 79:24-32.
20. Peck MW. 2009. Biology and genomic analysis of Clostridium botulinum. Adv. Microb. Physiol. 55:183-320. http://dx.doi.org/10.1016/S0065-2911 (09)05503-9.
21. Malizio CJ, Goodnough MC, Johnson EA. 2000. Purification of Clostridium botulinum type A neurotoxin. Methods Mol. Biol. 145:27-39.
22. Gimenez DF. 1984. Clostridium botulinum subtype Ba. Zentralbl. Bakteriol. Mikrobiol. Hyg. A 257:68-72.
23. Hatheway CL, McCroskey LM, Lombard GL, Dowell VR, Jr. 1981. Atypical toxin variant of Clostridium botulinum type B associated with infant botulism. J. Clin. Microbiol. 14:607-611.
24. Bradshaw M, Dineen SS, Maks ND, Johnson EA. 2004. Regulation of neurotoxin complex expression in Clostridium botulinum strains 62A, Hall A-hyper, and NCTC 2916. Anaerobe 10:321-333. http://dx.doi.org/10.1016/j.anaerobe.2004.07.001.
25. Lin G, Tepp WH, Pier CL, Jacobson MJ, Johnson EA. 2010. Expression of the Clostridium botulinum A2 neurotoxin gene cluster proteins and characterization of the A2 complex. Appl. Environ. Microbiol. 76:40-47. http://dx.doi.org/10.1128/AEM.01882-09.
26. Gimenez DF, Gimenez JA. 1983. Identification of strain B 657 of Clostridium botulinum. Rev. Argent. Microbiol. 15:51-55.
27. Dolly JO, Wang J, Zurawski TH, Meng J. 2011. Novel therapeutics based on recombinant botulinum neurotoxins to normalize the release of transmitters and pain mediators. FEBS J. 278:4454-4466. http://dx.doi.org/10.1111/j.1742-4658.2011.08205.x.
28. Rummel A, Mahrhold S, Bigalke H, Binz T. 2011. Exchange of the H(CC) domain mediating double receptor recognition improves the pharmacodynamic properties of botulinum neurotoxin. FEBS J. 278: 4506-4515. http://dx.doi.org/10.1111/j.1742-4658.2011.08196.x.
29. Gu S, Rumpel S, Zhou J, Strotmeier J, Bigalke H, Perry K, Shoemaker CB, Rummel A, Jin R. 2012. Botulinum neurotoxin is shielded by NTNHA in an interlocked complex. Science 335:977-981. http://dx.doi.org/10.1126/science.1214270.
30. Webb RP, Smith TJ, Wright P, Brown J, Smith LA. 2009. Production of catalytically inactive BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against toxin subtypes A1, A2, and A3. Vaccine 27:4490-4497. http://dx.doi.org/10.1016/j.vaccine.2009.05.030.
31. Band PA, Blais S, Neubert TA, Cardozo TJ, Ichtchenko K. 2010. Recombinant derivatives of botulinum neurotoxin A engineered for trafficking studies and neuronal delivery. Protein Expr. Purif. 71:62-73. http://dx.doi.org/10.1016/j.pep.2009.12.013.
32. Henkel JS, Jacobson M, Tepp W, Pier C, Johnson EA, Barbieri JT. 2009. Catalytic properties of botulinum neurotoxin subtypes A3 and A4. Biochemistry 48:2522-2528. http://dx.doi.org/10.1021/bi801686b.
33. Heap JT, Pennington OJ, Cartman ST, Carter GP, Minton NP. 2007. The ClosTron: a universal gene knock-out system for the genus Clostridium. J. Microbiol. Methods 70:452-464. http://dx.doi.org/10.1016/j.mimet.2007.05.021.
34. Heap JT, Kuehne SA, Ehsaan M, Cartman ST, Cooksley CM, Scott JC, Minton NP. 2010. The ClosTron: mutagenesis in Clostridium refined and streamlined. J. Microbiol. Methods 80:49-55. http://dx.doi.org/10.1016/j.mimet.2009.10.018.
35. Bradshaw M, Marshall KM, Heap JT, Tepp WH, Minton NP, Johnson EA. 2010. Construction of a nontoxigenic Clostridium botulinum strain for food challenge studies. Appl. Environ. Microbiol. 76:387-393. http://dx.doi.org/10.1128/AEM.02005-09.
36. Hatheway CL, Ferreira JL. 1996. Detection and identification of Clostridium botulinum neurotoxins. Adv. Exp. Med. Biol. 391:481-498. http://dx.doi.org/10.1007/978-1-4613-0361-9_39.
37. Heap JT, Pennington OJ, Cartman ST, Minton NP. 2009. A modular system for Clostridium shuttle plasmids. J. Microbiol. Methods 78:79-85. http://dx.doi.org/10.1016/j.mimet.2009.05.004.
38. Goodnough MC, Hammer B, Sugiyama H, Johnson EA. 1993. Colony immunoblot assay of botulinal toxin. Appl. Environ. Microbiol. 59:2339-2342.
39. Gimenez JA, Sugiyama H. 1987. Simplified purification method for Clostridium botulinum type E toxin. Appl. Environ. Microbiol. 53:2827-2830.
40. Schantz EJ, Kautter DA. 1978. Standardized assay for Clostridium botulinum toxins. J. Assoc. Off. Anal. Chem. 61:96-99.
41. Reed LJ, Muench H. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. (Lond.) 27:493-497.
42. Woody MA, DasGupta BR. 1988. Fast protein liquid chromatography of botulinum neurotoxin types A, B and E. J. Chromatogr. 430:279-289. http://dx.doi.org/10.1016/S0378-4347(00)83163-1.
43. Whitemarsh RC, Strathman MJ, Chase LG, Stankewicz C, Tepp WH, Johnson EA, Pellett S. 2012. Novel application of human neurons derived from induced pluripotent stem cells for highly sensitive botulinum neurotoxin detection. Toxicol. Sci. 126:426-435. http://dx.doi.org/10.1093/toxsci/kfr354.
44. Pellett S, Tepp WH, Clancy CM, Borodic GE, Johnson EA. 2007. A neuronal cell-based botulinum neurotoxin assay for highly sensitive and specific detection of neutralizing serum antibodies. FEBS Lett. 581:4803-4808. http://dx.doi.org/10.1016/j.febslet.2007.08.078.
45. Pellett S, Tepp WH, Toth SI, Johnson EA. 2010. Comparison of the primary rat spinal cord cell (RSC) assay and the mouse bioassay for botulinum neurotoxin type A potency determination. J. Pharmacol. Toxicol. Methods 61:304-310. http://dx.doi.org/10.1016/j.vascn.2010.01.003.
46. Gimenez DF, Gimenez JA. 1993. Serological subtypes of botulinum of botulinal neurotoxins, p 421-431. In Dasgupta BR (ed), Botulism and tetanus neurotoxins: neurotransmission and biomedical aspects. Plenum Press, New York, NY.
47. Gimenez DF, Ciccarelli AS. 1970. Studies on strain 84 of Clostridium botulinum. Zentralbl. Bakteriol. Orig. 215:212-220.
48. Schmidt JJ, Sathyamoorthy V, DasGupta BR. 1984. Partial amino acid sequence of the heavy and light chains of botulinum neurotoxin type A. Biochem. Biophys. Res. Commun. 119:900-904. http://dx.doi.org/10.1016/0006-291X(84)90858-1.
49. Jacobson MJ, Lin G, Tepp W, Dupuy J, Stenmark P, Stevens RC, Johnson EA. 2011. Purification, modeling, and analysis of botulinum neurotoxin subtype A5 (BoNT/A5) from Clostridium botulinum strain A661222. Appl. Environ. Microbiol. 77:4217-4222. http://dx.doi.org/10.1128/AEM.00201-11.